ストックスクリーナーアプリを入手
89.71
0.02%
0.02
アフターアワーズ：
89.71
前日終値:
$89.69
開ける：
$89.73
24時間の取引高:
1.56M
Relative Volume:
0.29
時価総額：
$33.85B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
38.37
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
+0.47%
1か月 パフォーマンス:
+2.75%
6か月 パフォーマンス:
+22.76%
1年 パフォーマンス:
+13.67%
1日の値動き範囲:
$89.05
$91.00
1週間の範囲:
$88.83
$92.33
52週間の値動き範囲:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
89.71 | 34.05B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
108.79 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.10 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.99 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.95 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.78 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Act - The National Law Review
DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake - Dealroom
Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM - MarketBeat
Trillium Asset Management LLC Invests $3.23 Million in DexCom, Inc. $DXCM - MarketBeat
Danske Bank A S Purchases New Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup - ChartMill
Dexcom stock holds close to analyst target as growth story stays intact - Ad-hoc-news.de
E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM - MarketBeat
Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM - MarketBeat
Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in DexCom, Inc. $DXCM - MarketBeat
12,080 Shares in DexCom, Inc. $DXCM Bought by Alamar Capital Management LLC - MarketBeat
Dexcom stock edges higher as Q1 2026 growth and CGM demand support valuation - Ad-hoc-news.de
Flputnam Investment Management Co. Makes New Investment in DexCom, Inc. $DXCM - insurancenewsnet.com
Performance Wealth Partners LLC Takes Position in DexCom, Inc. $DXCM - MarketBeat
GSA Capital Partners LLP Takes $1.33 Million Position in DexCom, Inc. $DXCM - MarketBeat
Global Retirement Partners LLC Purchases Shares of 20,784 DexCom, Inc. $DXCM - MarketBeat
Provident Investment Management, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow - Yahoo Finance
DexCom Inc (MIL:1DXCM) Stock Price, Trades & News - GuruFocus
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) legal chief sells stock under 10b5-1 plan - Stock Titan
DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued? - Yahoo Finance
Dexcom stock trades at premium valuation as margins improve and targets rise - Ad-hoc-news.de
Nippon Life Global Investors Americas Inc. Buys Shares of 53,400 DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM): Investor Outlook on a Leading Medical Device Innovator with Strong Buy Ratings - DirectorsTalk Interviews
DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates - Yahoo Finance
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bridgewater Advisors Inc. Invests $1.08 Million in DexCom, Inc. $DXCM - MarketBeat
43,005 Shares in DexCom, Inc. $DXCM Bought by SWS Partners - MarketBeat
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Wall Street Bullish or Bearish on DexCom Stock? - Yahoo Finance
Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs - Stock Titan
ETFs Investing in DexCom, Inc. Stocks - TradingView
Dexcom stock holds above $90 as strong Q2 2026 margins support a raised outlook - AD HOC NEWS
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago - Yahoo Finance
Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? - TradingView
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? - TradingView
DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade - Stock Titan
Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM) - webull.com
E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM - MarketBeat
DexCom stock hits 52-week high at 87.85 USD By Investing.com - Investing.com UK
DexCom Inc (DXCM) Stock Up 3.4% and Still Undervalued -- GF Scor - GuruFocus
DexCom (NASDAQ:DXCM) Reaches New 1-Year HighWhat's Next? - MarketBeat
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
1.19%
大文字化:
|
ボリューム (24 時間):